EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia /small lymphocytic lymphoma



MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia /small lymphocytic lymphoma



Japanese Journal of Cancer Research 93(6): 685-694, June



B-Cell chronic lymphocytic leukemia (B-CLL)/small lymphocytic lymphoma (SLL) consists of heterogeneous diseases that are distinguished by morphological, immunophenotypic and molecular features. MUM1 (multiple myeloma oncogene 1) is a protooncogene that is deregulated as a result of (6;14)(p25;q32) chromosomal translocation in multiple myeloma, and is also expressed in a variety of malignant lymphoma entities. We examined the expression of MUM1 in B-CLL/SLL, and found that 2 of 4 B-CLL-derived cell lines and 14 of 29 patients' specimens expressed MUM1 by immunohistochemical analysis. MUM1 expression was not associated with CD38 expression, somatic hypermutation of immunoglobulin heavy chain gene variable region (IgVH), or any other clinical characteristics of the patients. Interestingly, the patients who were positive for MUM1 showed shorter overall survival times than those who were negative for MUM1 (50% survival: 22 months vs. 82 months) (P=0.0008, log-rank test). Multivariate analysis by Cox's proportional-hazards regression model showed that MUM1 expression and unmutated IgVH status were independent unfavorable prognostic factors in patients with B-CLL/SLL. These findings suggest that MUM1 expression is a useful prognostic factor in B-CLL/SLL. The biological role and mechanism of action of MUM1 in B-CLL/SLL need to be clarified for the development of therapies for patients with the poor prognostic subtype.

(PDF emailed within 1 workday: $29.90)

Accession: 035251067

Download citation: RISBibTeXText



Related references

MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Japanese Journal of Cancer Research 93(6): 685-694, 2002

Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 100(13): 4671-4675, 2002

Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Archiv 468(2): 141-157, 2016

MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia. Leukemia & Lymphoma 49(2): 273-280, 2008

Aberrant expression of antigens in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. Cytometry (SUPPL 9): 108, 1998

Limitations of using CD23 expression by flow cytometry to differentiate mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood 96(11 Part 1): 330a, November 16, 2000

Does analysis of cyclin D1 expression by quantitative real time RT-PCR differentiate between mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma?. Blood 96(11 Part 2): 229b, November 16, 2000

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clinic Proceedings 79(3): 318-325, 2004

High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. American Journal of Clinical Pathology 132(4): 589-596, 2009

The prognostic significance of cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). 2007

The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Human Pathology 37(2): 152-159, 2006

Immunohistochemical characteristics of monocytoid B cell lymphoma, mantle zone lymphoma, small lymphocytic lymphoma (or B chronic lymphocytic leukemia), and hairy cell leukemia. Acta Haematologica 90(2): 84-89, 1993

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma 58(6): 1349-1357, 2017

Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. Journal of Clinical and Experimental Hematopathology, 2018

CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cytometry. Part B, Clinical Cytometry (): -, 2016